In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.

Mcgill University Medical Podcast Series

Mcgill University Medical Podcast Series

Episode 4 - Dr. Richard Menzies and Dr. Jonathan Campbell - 4 months of Rifampin for latent TB

FEB 9, 201918 MIN
Mcgill University Medical Podcast Series

Episode 4 - Dr. Richard Menzies and Dr. Jonathan Campbell - 4 months of Rifampin for latent TB

FEB 9, 201918 MIN

Description

In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.